Acrivastine
Semprex-d (acrivastine) is a small molecule pharmaceutical. Acrivastine was first approved as Semprex-d on 1994-03-25. It is used to treat allergic rhinitis perennial and urticaria in the USA.
Trade Name | Semprex-d |
---|---|
Common Name | Acrivastine |
Indication | allergic rhinitis perennial, urticaria |
Drug Class | Antihistaminics (histamine-H1 receptor antagonists) |